Vancomycin-induced nephrotoxicity in non-intensive care unit pediatric patients

Shinhyeung Kwak1,2, Jeong Yeon Kim1,2 & Heeyeon Cho1*

Previous data suggested several risk factors for vancomycin-induced nephrotoxicity (VIN), including higher daily dose, long-term use, underlying renal disease, intensive care unit (ICU) admission, and concomitant use of nephrotoxic medications. We conducted this study to investigate the prevalence and risk factors of VIN and to estimate the cut-off serum trough level for predicting acute kidney injury (AKI) in non-ICU pediatric patients. This was a retrospective, observational, single-center study at Samsung Medical Center tertiary hospital, located in Seoul, South Korea. We reviewed the medical records of non-ICU pediatric patients, under 19 years of age with no evidence of previous renal insufficiency, who received vancomycin for more than 48 h between January 2009 and December 2018. The clinical characteristics were compared between patients with AKI and those without to identify the risk factors associated with VIN, and the cut-off value of serum trough level to predict the occurrence of VIN was calculated by the Youden's index. Among 476 cases, 22 patients (4.62%) developed AKI. The Youden's index indicated that a maximum serum trough level of vancomycin above 24.35 μg/mL predicted VIN. In multivariate analysis, longer hospital stay, concomitant use of piperacillin-tazobactam and serum trough level of vancomycin above 24.35 μg/mL were associated independently with VIN. Our findings suggest that concomitant use of nephrotoxic medication and higher serum trough level of vancomycin might be associated with the risk of VIN. This study suggests that measuring serum trough level of vancomycin can help clinicians prevent VIN in pediatric patients.

Vancomycin, a glycopeptide antibiotic, has been the first-line therapy for methicillin-resistant Staphylococcus aureus (MRSA) since it was discovered in 1952, and it is widely used to treat Gram-positive bacterial infections in patients who are allergic to penicillin. However, vancomycin-induced nephrotoxicity (VIN) has been reported in pediatric and adult patients and presents a challenge for the broad use of vancomycin. Studies have suggested that vancomycin could induce nephrotoxicity by free radical production and subsequent oxidative stress and mitochondrial damage, but the exact mechanism has not been determined. In pediatric patients, the incidence of VIN has not been well established, and the prevalence was reported to range from 2.4 to 27.2% depending on the study population. It is presumed that the prevalence of VIN could differ depending on whether the study population is comprised of intensive care unit (ICU) patients, but there is little data on this specific issue. Previous data suggested several risk factors of VIN, including higher daily dose, prolonged duration of treatment, underlying renal disease, ICU admission, and concomitant nephrotoxic medications. However, these predisposing factors differed depending on study population, and no study has analyzed the variables for non-ICU pediatric patients.

Correlation between serum level of vancomycin and occurrence of VIN remains unclear. Many studies have not identified a significant relationship between serum trough level of vancomycin and development of nephrotoxicity. Several studies have reported that serum trough level of vancomycin ≥ 15 μg/mL is a risk factor for VIN in children as well as in adults, but most of those studies included ICU patients, who generally are severely ill, compared with non-ICU patients and might have included additional risk factors for VIN. The 2011 Infectious Diseases Society of America guidelines for vancomycin use in pediatrics stated that a vancomycin trough level of 15–20 μg/mL could be targeted for patients with severe MRSA infections, such as osteomyelitis, infective endocarditis, meningitis, and bacteremia. This recommendation is extrapolated from adult studies but lacks evidence in pediatric patients. There are limited data in pediatric patients to suggest that monitoring the serum trough level of vancomycin improves outcomes; additionally, it is not known whether the current recommendation for trough level of vancomycin is safe to prevent VIN and if the target is effective for treating

1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea. These authors contributed equally: Shinhyeung Kwak and Jeong Yeon Kim. email: choheeyeon@gmail.com
patients with severe infection. The purpose of this study was to investigate the prevalence of VIN and associated risk factors and to analyze cut-off value of serum trough level of vancomycin to predict the occurrence of VIN in non-ICU pediatric patients.

**Methods**

**Study population.** This single-center, retrospective, observational study was conducted at Samsung Medical Center (Seoul, South Korea) from January 1, 2009, to December 31, 2018, by electronic medical record review. Pediatric patients (age of 3 months–19 years) that were admitted in the general ward and received vancomycin for more than 48 h were included. We excluded patients that had a baseline estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m², underlying kidney disease, a history of renal replacement therapy at the time of admission, or incomplete data for serum creatinine or body measurements.

All data were obtained from electronic medical records and analyzed in accordance with the ethical principles for medical research involving human subjects established in the Declaration of Helsinki of 1975, and revised in 2000. The informed consent was waived by the Institutional Review Board (IRB) of Samsung Medical Center which approved this study (IRB number 2020-12-017). The following clinical data were collected; age, sex, height, weight, serum blood urea nitrogen (BUN) and creatinine levels, length of hospital stay in days, duration of vancomycin therapy, vancomycin trough level, underlying conditions, inotropic or vasopressor medication use during vancomycin therapy to assess the clinical severity, concomitant nephrotoxic medications including loop diuretics, piperacillin/tazobactam (PIP/TAZ), angiotensin converting enzyme inhibitors (ACEi), and angiotensin II receptor blockers (ARB) which are prescribed at least once during vancomycin therapy.

**Definitions.** Baseline serum creatinine was defined as the value measured at the time before vancomycin therapy. The eGFR was calculated using the original Schwartz formula\(^{12-14}\). Acute kidney injury (AKI) immediately after or during the use of vancomycin was considered VIN. Kidney injury was classified based on the Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease (pRIFLE) criteria\(^{15}\) and AKI was defined as eGFR decreased over 50%, which can be presented as Injury or Failure in pRIFLE criteria\(^{15}\). The serum trough level of vancomycin initially was measured within 24 h after administration of vancomycin. The highest trough level measured during vancomycin therapy was collected and defined as the maximum vancomycin trough level.

**Monitoring vancomycin serum trough level.** Our center guidelines require the serum trough level of vancomycin measurement to be captured just before the 5th dose administration or 24 h after the first administration of vancomycin. The clinical pharmacokinetic service (Abbottbase\textsuperscript{®} Pharmacokinetic System, version 1.10) of the Center is used by physicians to discuss and adjust the dosage of vancomycin with clinical pharmacists based on patient-specific pharmacokinetic factors. Serum trough level of vancomycin is measured every 24 h.

**Statistical analysis.** Statistical analysis was performed using SPSS version 27.0 software, and a p value < 0.05 was considered statistically significant. For bivariate analyses, the categorical variables were compared using χ\(^2\) or the Fisher’s exact test, and continuous variables were assessed using Student’s t-test and the nonparametric Wilcoxon rank-sum test, when appropriate. Multivariable logistic regression was applied to analyze the risk factors for VIN. Variables with a p-value less than 0.1 in univariate logistic regression and variables thought to be clinically meaningful were considered, and a final model was constructed through variable selection using the stepwise selection method. The cut-off value of maximum trough level of vancomycin to predict VIN occurrence was calculated by the Youden’s index.

**Ethical approval.** The Institutional Review Board (IRB) of Samsung Medical Center approved this study (IRB number 2020-12-017).

**Results**

**Demographic and clinical data and AKI prevalence.** A total of 476 vancomycin-treated non-ICU pediatric cases was included in the analysis. There was a higher prevalence of male patients in this study (male-to-female ratio: 1.47), and the mean age at the start of vancomycin administration was 8.3 years. The mean baseline eGFR was 190.45 mL/min/1.73m². The mean maximum trough level of vancomycin was 18.79 μg/mL. In 129 cases, concomitant nephrotoxic medications were used during vancomycin therapy. The most common underlying disease was hematopoietic disease (61.6%), and 14.9% patients had no underlying disease.

A total of 22 patients (4.6%) developed AKI during vancomycin treatment; 20 cases of Injury (4.2%), and 2 cases of Failure (0.4%). The prevalence of AKI according to the patient age was follows; < 1 year 10.0%, 1–2 year 4.2%, 2–3 year 7.7%, 3–4 year 3.5%, 4–5 year 2.8%, 6–7 year 13.0%, 9–10 year 13.3%, 11–12 year 4.2%, 13–14 year 5.3%, 14–15 year 13.0%, 16–17 year 3.7% and no AKI in 5–6, 7–9, 10–11, 12–13 and 15–18 year. Most of the VIN cases recovered to normal renal function, although one progressed to chronic kidney disease (CKD) stage 2. Patient demographics are summarized in Table 1.

**VIN group comparisons.** The results for the VIN group and group without VIN are shown in Table 2. The following variables showed significant association with the occurrence of VIN: longer duration of vancomycin therapy (13.7 days vs. 9.8 days, p = 0.018), greater number of days of hospitalization (45.4 days vs. 25.2 days, p = 0.01), higher maximum vancomycin trough level (23.5 μg/mL vs. 18.6 μg/mL, p = 0.013), and concomitant use of nephrotoxic medications (furosemide; 40.9% vs. 21.2%, p = 0.0367, PIP/TAZ; 22.7% vs. 4.4%, p = 0.0038).
There was no concomitant use of inotropic or vasopressor medication during vancomycin therapy in the VIN group.

**Contributing factors for VIN.** The number of days of hospitalization, duration of vancomycin therapy, concomitant use of furosemide or PIP/TAZ, and vancomycin trough level were associated independently with the occurrence of VIN (Table 3). Multivariate logistic regression analysis showed that longer hospital days (OR 1.008, \( p = 0.0434 \)), a maximum vancomycin trough level over 24.35 μg/mL (OR 3.519, \( p = 0.006 \)) and concomitant use of PIP/TAZ (OR = 4.407, \( p = 0.0128 \)) increased the risk of VIN (Table 4).

**Optimal vancomycin trough level for AKI prediction.** To predict VIN in non-ICU pediatric patients, the optimal cut-off value for the maximum vancomycin trough level was estimated by Youden’s index. A maximum trough level of vancomycin above 24.35 μg/mL predicted VIN in non-ICU children (sensitivity 50%, specificity 79.3%, accuracy 77.9%). Receiver operating characteristic (ROC) curve analysis indicated that the area under the ROC curve (AUC) was 0.6573 (95% confidence interval 0.5394–0.7752, \( p = 0.0089 \)) (Fig. 1).

**Discussion**

This study evaluated the prevalence and associated risk factors of VIN in non-ICU pediatric patients. Previous studies have reported a wide range of VIN incidence, from 2.4 to 27.2\%\textsuperscript{4–6}, which is likely due to clinical differences in the study population, as well as heterogeneity in vancomycin dosing and the definition of VIN\textsuperscript{5,7,16,17}.

In this study, AKI occurred in 4.6\% of 476 vancomycin-treated non-ICU pediatric patients, which was relatively low compared to previous reports. This difference is likely because our study was performed to assess non-ICU pediatric patients with relatively stable vital signs.

In this study, PIP/TAZ use independently increased the risk of VIN occurrence, which is consistent with previous reports\textsuperscript{5,11,16,18–20}. A previous study indicated that children with renal insufficiency were more likely to receive furosemide compared with children with normal kidney function\textsuperscript{11}. The risk of VIN in children that receive furosemide might be attributable to baseline renal insufficiency and to the additional nephrotoxicity caused by furosemide. For patients that received PIP/TAZ, it is unclear whether the risk of VIN is due to the severity of infection or synergistic drug toxicity. We also investigated whether the use of ACEi or ARB, and

---

**Table 1.** Patient demographic and clinical data. ICU intensive care unit, SD standard deviation, eGFR estimated glomerular filtration rate, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blocker.
Table 2. Clinical characteristics of patients with and without VIN. *Data are presented as the mean with standard deviation. VIN vancomycin-induced nephrotoxicity, AKI acute kidney injury, eGFR estimated glomerular filtration rate, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blocker.

| Variable                                                                 | AKI (n=22)       | Non-AKI (n=454)  | p-value  |
|-------------------------------------------------------------------------|------------------|------------------|----------|
| Male: Female (ratio)                                                    | 14:8 (1.75)      | 269:185 (1.45)   | 0.6824   |
| Age at vancomycin treatment (years)*                                    | 6.67 ± 5.71      | 8.37 ± 5.91      | 0.143    |
| Length of hospital stay (days)*                                         | 45.36 ± 42.46    | 25.18 ± 33.65    | 0.0001   |
| Baseline eGFR (mL/min/1.73m²)*                                          | 282.62 ± 127.66  | 185.99 ± 71.61   | <0.0001  |
| Duration of vancomycin therapy (days)*                                 | 13.73 ± 9.70     | 9.78 ± 8.64      | 0.018    |
| Duration from initial vancomycin administration to initial trough level (hours)* | 27.16 ± 13.56    | 30.5 ± 22.3      | 0.4297   |
| Duration from initial vancomycin administration to maximum trough level (hours)* | 178.79 ± 154.02  | 125.01 ± 117.18  | 0.1122   |
| Initial trough level of vancomycin (μg/mL)*                            | 15.10 ± 12.84    | 10.94 ± 9.85     | 0.0687   |
| Maximum trough level of vancomycin (μg/mL)*                            | 23.46 ± 11.30    | 18.56 ± 12.28    | 0.013    |
| Use of inotropic or Vasopressor medication, n (%)                       | 0                | 13 (2.86)        | 0.0367   |

Table 3. Univariate logistic regression analysis of independent risk factors for VIN. VIN vancomycin-induced nephrotoxicity, OR odds ratio, CI confidence interval, BUN blood urea nitrogen. Continuous variable odds ratio is odds per single unit indicated in parenthesis.

| Variable                                                                 | OR    | 95% CI          | p-value  |
|-------------------------------------------------------------------------|-------|-----------------|----------|
| Hospital day (day)                                                      | 1.009 | 1.002–1.017     | 0.0149   |
| Concomitant nephrotoxic agents                                          |       |                 |          |
| Furosemide, n (%)                                                       | 2.582 | 1.072–6.220     | 0.0345   |
| Piperacillin/tazobactam, n (%)                                          | 6.382 | 2.139–19.045    | 0.0009   |
| Combined administration, n (%)                                          | 1.615 | 0.202–12.937    | 0.6514   |
| Vancomycin treatment duration (day)                                     | 1.034 | 1.000–1.069     | 0.0474   |
| Vancomycin trough concentration                                         |       |                 |          |
| Maximum trough level ≥ 24.35 μg/mL                                     | 3.83  | 1.611–9.105     | 0.0024   |
| Initial trough level (μg/mL)                                            | 1.021 | 0.996–1.046     | 0.0984   |
| Maximum trough value (μg/mL)                                            | 1.02  | 0.997–1.042     | 0.0873   |
| Average trough value over 72 h (μg/mL)                                  | 1.053 | 0.997–1.113     | 0.0616   |
inotropic or vasopressor medications could influence the occurrence of VIN and determined that there was no association between the occurrence of VIN and the use of these medications in non-ICU pediatric patients.

Vancomycin trough level has been evaluated commonly as a potential predictor of nephrotoxicity in many previous studies. Several studies in adults have reported that the risk of AKI increases as the trough level of vancomycin increases\(^8\),\(^{21}\), but data in children are limited. While the guidelines recommend vancomycin trough level of 15–20 μg/mL to achieve more effective overall antibiotic exposure in severe infectious diseases, a few studies in pediatric patients have assessed the safety of this recommendation by comparing the incidence of nephrotoxicity of children with values above these ranges and those with values below 15 μg/mL\(^5\),\(^6\),\(^11\). The ideal therapeutic trough level for preventing nephrotoxic AKI has not been confirmed. In this study, the cut-off value of trough level to predict nephrotoxicity was calculated by Youden’s J statistical analysis. When this estimated cut-off value was applied, both univariate and multivariate logistic regression analyses showed that vancomycin trough level ≥ 24.35 μg/mL is a risk factor for VIN. With the limitation of retrospective study design of this study, we do not know the causal relationship between the over 24.35 μg/mL vancomycin trough level and AKI. However, this finding suggests that regular monitoring of vancomycin trough level and effort to keep the level below 24.35 μg/mL could be helpful to prevent VIN in non-ICU pediatric patients. Despite the low value of AUC 0.6573, which indicates the risk of low accuracy, the negative predictive value was 97.04%, which suggested that the risk of AKI could be reduced under conditions where the serum trough level is below 24.35 μg/mL. Moreover, according to these results, targeting a vancomycin trough level of 15–20 μg/mL for severe infections, as indicated in the current guidelines, could be justified for non-ICU pediatric patients without underlying kidney disease. Furthermore, in the previous reported meta-analysis, the diagnostic accuracy analysis of AKI according to vancomycin trough value demonstrated AUC 0.681 and 0.637 in vancomycin trough level of 15 and 20 μg/mL, respectively\(^22\). These consistently low AUC values, including the result from this study, might indicate the presence of the unobserved variable, which need to be revealed in future research.

### Table 4. Multivariate logistic regression analysis of risk factors for VIN. VIN vancomycin-induced nephrotoxicity, OR odds ratio, CI confidence interval. Continuous variable odds ratio is odds per single unit indicated in parenthesis.

| Variable                                      | OR     | 95% CI          | p value |
|-----------------------------------------------|--------|-----------------|---------|
| Hospital days (day)                           | 1.008  | 1.000–1.017     | 0.0434  |
| Concomitant Piperacillin/tazobactam           | 4.407  | 1.370–14.170    | 0.0128  |
| Maximum vancomycin trough concentration ≥ 24.35 μg/mL | 3.519  | 1.434–8.632     | 0.0060  |

### Figure 1. ROC curve to estimate the optimal cut-off value for maximum trough level of vancomycin (AUC = 0.6573).
Previous studies have shown that the number of days in hospital and duration of vancomycin treatment are related to occurrence of AKI. In our study, the total durations of hospitalization and vancomycin therapy were significantly longer in the group with nephrotoxicity than in the group without nephrotoxicity. However, in multivariate analysis, only duration of hospitalization was associated to VIN. It is possible that the longer hospitalization and prolonged vancomycin use could be related to disease severity and highly influenced by many other variables.

Even though most cases of AKI that are induced by vancomycin treatment recovered in our study, one patient progressed to CKD stage 2. The case with CKD was a 6-month-old boy that had underlying disease with biliary atresia and was treated with vancomycin for 10 days with concomitant use of furosemide.

With aforementioned limitation of retrospective study, we do not know the causal relationship between risk factors revealed in this study and VIN. However, for the non-ICU pediatric patients with the VIN risk contributing factors, clinicians could have chance to re consider alternative antibiotics for gram-positive bacterial infection such as teicoplanin which is known to be less nephrotoxic and similar effect compare to vancomycin.

Our study had some limitations. First, more than half of the patients in this study had underlying disease with malignancy, and their renal function could have been impacted because of the previous exposure to nephrotoxic agents. Second, this study was a single center and retrospective study in which it was difficult to control the actual time of blood sample collection. Third, the low prevalence of VIN in this study might have impacted the power of statistical analysis. In order to minimize the bias (under- and over-estimation) of multiple logistic regression, variable selection was required to create a final model consisting of only important variables, and a variable selection method called stepwise selection method was used. For validation, a further multicenter large sample study could be helpful. Finally, several factors that could affect nephrotoxicity, such as intravenous contrast dye were not evaluated because of the limited available data.

Conclusion
The prevalence of VIN in non-ICU pediatric patients was 4.6% in our study, and concomitant nephrotoxic agents such as PIP/TAZ and higher serum trough level of vancomycin were risk factors for VIN. Therefore, predicting the risk for AKI based on the highest trough level of vancomycin can help clinicians identify and prevent VIN in non-ICU pediatric patients.

Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Code availability
Statistical analysis was performed using SPSS version 27.0 software.

Received: 1 July 2021; Accepted: 7 October 2021
Published online: 19 October 2021

References
1. Liu, C., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52, 285–292. https://doi.org/10.1093/cid/cot34 (2011).
2. King, D. W. & Smith, M. A. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol In Vitro 18, 797–803. https://doi.org/10.1016/j.tiv.2004.03.013 (2004).
3. Elyasi, S., Khalili, H., Dashi-Khavidaki, S. & Mohammadpour, A. Vancomycin-induced nephrotoxicity: Mechanism, incidence, risk factors and special populations. A literature review. Eur. J. Clin. Pharmacol. 68, 1243–1255. https://doi.org/10.1007/s00228-012-1259-9 (2012).
4. Jeffres, M. N. The whole price of vancomycin: Toxicities, troughs, and time. Drugs 77, 1143–1154. https://doi.org/10.1007/s40265-017-0764-7 (2017).
5. Fiorito, T. M., Luther, M. K., Dennehy, P. H., LaPlante, K. L. & Matson, K. L. Nephrotoxicity with vancomycin in the pediatric population: A systematic review and meta-analysis. Pediatr. Infect. Dis. J. 37, 654–661. https://doi.org/10.1097/INF.0000000000001882 (2018).
6. Filipponne, E. J., Kraft, W. K. & Farber, J. I. The nephrotoxicity of vancomycin. Clin. Pharmacol. Ther. 102, 459–469. https://doi.org/10.1002/cpt.726 (2017).
7. Sinclair, E. A. et al. Factors associated with acute kidney injury in children receiving vancomycin. Ann. Pharmacother. 48, 1555–1562. https://doi.org/10.1177/1060028014549185 (2014).
8. Park, S. J. et al. Evaluation of risk factors for vancomycin-induced nephrotoxicity. Int. J. Clin. Pharm. 40, 1328–1334. https://doi.org/10.1007/s11096-018-0634-8 (2018).
9. Jorgensen, S. C. J. et al. A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections. Infect. Dis. Ther. 9, 89–106. https://doi.org/10.1007/s40121-019-00278-1 (2020).
10. Feiten, H. D. S. et al. Vancomycin-associated nephrotoxicity and risk factors in critically ill children without preexisting renal injury. Pediatr. Infect. Dis. J. 38, 934–938. https://doi.org/10.1097/INF.0000000000002391 (2019).
11. Zhang, H. et al. Baseline kidney function is associated with vancomycin-induced acute kidney injury in children: a prospective nested case-control study. Pediatr. Nephrol. 36, 1299–1306. https://doi.org/10.1007/s00467-020-04820-2 (2021).
12. Schwartz, G. J., Brion, L. P. & Spitzer, A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. North Am. 34, 571–590. https://doi.org/10.1016/0031-3955(87)90251-4 (1987).
13. Schwartz, G. J., Haycock, G. B., Edelman, C. M., Jr. & Spitzer, A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatr. Nephrol. 28, 259–263 (1976).
14. Brion, L. P., Fleischman, A. R., McCartney, C. & Schwartz, G. J. A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: Noninvasive assessment of body composition and growth. J. Pediatr. 109, 698–707. https://doi.org/10.1016/S0022-3476(86)80245-1 (1986).
15. Soler, Y. A., Nieves-Plaza, M., Prieto, M., García-De Jesus, R. & Suarez-Rivera, M. Pediatric risk, injury, failure, loss, end-stage renal disease score identifies acute kidney injury and predicts mortality in critically ill children: A prospective study. *Pediatr. Crit. Care Med.* **14**, 189–195. https://doi.org/10.1097/PCC.0b013e3182745675 (2013).
16. McKamy, S. *et al.* Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. *J. Pediatr.* **158**, 422–426. https://doi.org/10.1016/j.jpeds.2010.08.019 (2011).
17. Lodise, T. P., Lomaestro, B., Graves, J. & Drusano, G. L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. *Antimicrob. Agents Chemother.* **52**, 1330–1336. https://doi.org/10.1128/AAC.01602-07 (2008).
18. Navalkele, B. *et al.* Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. *Clin. Infect. Dis.* **64**, 116–123. https://doi.org/10.1093/cid/ciw709 (2017).
19. Carreno, J. J., Kenney, R. M. & Lomaestro, B. Vancomycin-associated renal dysfunction: Where are we now?. *Pharmacotherapy* **34**, 1259–1268. https://doi.org/10.1002/phar.1488 (2014).
20. Al Nuhait, M., Abu Esba, L. C., Al Harbi, K., Al Meshary, M. & Bustami, R. T. Acute kidney injury in pediatric treated with vancomycin and piperacillin-tazobactam in tertiary care hospital. *Int. J. Pediatr.* **2018**, 9256528. https://doi.org/10.1155/2018/9256528 (2018).
21. Bosso, J. A. *et al.* Relationship between vancomycin trough concentrations and nephrotoxicity: A prospective multicenter trial. *Antimicrob. Agents Chemother.* **55**, 5475–5479. https://doi.org/10.1128/AAC.00168-11 (2011).
22. Bellos, I., Daskalakis, G. & Pergialiotis, V. Relationship of vancomycin trough levels with acute kidney injury risk: An exposure-toxicity meta-analysis. *J. Antimicrob. Chemother.* **75**, 2725–2734. https://doi.org/10.1093/jac/dkaa184 (2020).
23. Cavalcanti, A. B., Goncalves, A. R., Almeida, C. S., Bugano, D. D. G. & Silva, E. Teicoplanin versus vancomycin for proven or suspected infection. *Cochrane Database Syst. Rev.* https://doi.org/10.1002/14651858.CD007022.pub2 (2010).

**Author contributions**

H.C. conceptualized, designed the study, and revised the manuscript; S.K. contributed to the analysis and drafted the manuscript; J.Y.K. collected the data and performed the analysis. All authors read and approved the manuscript.

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to H.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021